{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Afaq A"],"funding":["Engineering and Physical Sciences Research Council"],"pubmed_abstract":["<b>Objectives:</b> To assess the safety and clinical impact of a novel, kit-based formulation of <sup>68</sup>Ga-THP PSMA positron emission tomography/computed tomography (PET/CT) when used to guide the management of patients with prostate cancer (PCa). <b>Methods:</b> Patients were prospectively recruited in to one of: Group A: high-risk untreated prostate cancer; Gleason score >4+3, or PSA >20 ng/mL or clinical stage >T2c. Group B: biochemical recurrence (BCR) and eligible for salvage treatment after radical prostatectomy with two consecutive rises in prostate specific antigen (PSA) with a three month interval in between reads and final PSA >0.1 ng/mL or a PSA level >0.5 ng/mL. Group C: BCR with radical curative radiotherapy or brachytherapy at least three months prior to enrolment, and "],"journal":["Journal of nuclear medicine : official publication, Society of Nuclear Medicine"],"pagination":["jnumed.120.257527"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8612191"],"repository":["biostudies-literature"],"pubmed_title":["A Phase II, Open-label study to assess safety and management change using <sup>68</sup>Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study."],"pmcid":["PMC8612191"],"funding_grant_id":["EP/S032789/1"],"pubmed_authors":["Afaq A","Kelkar A","Bomanji J","Cook GJR","Mitra A","Orczyk C","Hines J","Priftakis D","Meagher M","Payne H","Davda R","Warbey VS","Mullen G","Needleman S","Ferris M"],"additional_accession":[]},"is_claimable":false,"name":"A Phase II, Open-label study to assess safety and management change using <sup>68</sup>Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study.","description":"<b>Objectives:</b> To assess the safety and clinical impact of a novel, kit-based formulation of <sup>68</sup>Ga-THP PSMA positron emission tomography/computed tomography (PET/CT) when used to guide the management of patients with prostate cancer (PCa). <b>Methods:</b> Patients were prospectively recruited in to one of: Group A: high-risk untreated prostate cancer; Gleason score >4+3, or PSA >20 ng/mL or clinical stage >T2c. Group B: biochemical recurrence (BCR) and eligible for salvage treatment after radical prostatectomy with two consecutive rises in prostate specific antigen (PSA) with a three month interval in between reads and final PSA >0.1 ng/mL or a PSA level >0.5 ng/mL. Group C: BCR with radical curative radiotherapy or brachytherapy at least three months prior to enrolment, and ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-05T08:59:08.606Z","creation":"2024-11-08T17:59:18.427Z"},"accession":"S-EPMC8612191","cross_references":{"pubmed":["33741648"],"doi":["10.2967/jnumed.120.257527"]}}